Xilio Therapeutics, Inc. (XLO)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $9.02
- As of
Kresmion compiles this page from XLO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Xilio Therapeutics, Inc. (XLO): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-12.
See the full XLO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for XLO on one page. Preview it with sample data, then open it live with a free account.
Preview the XLO dossierActive signals for XLO
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 44.6%, EPS $-0.33 vs $-0.5959 estimate
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in XLO
- mediumNEW_POSITION
TWO SIGMA INVESTMENTS, LP new position in XLO
- mediumNEW_POSITION
RENAISSANCE TECHNOLOGIES LLC new position in XLO
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 98.0% - EPS $-2.24 vs $-1.1312 estimate
FREE, NO ACCOUNT
Every signal on XLO, as it fires
You are seeing 5 of 8 signals recorded on XLO since 2026-05-26.
The five above landed across 4 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in XLO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 98422T209 · 2026Q2 | $615K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 98422T209 · 2026Q2 | $249K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 98422T209 · 2026Q2 | $139K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, XLO
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
XLO against its peers
XLO's operating margin of -95.9% ranks in the 68th percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | XLO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 43.8M USD | 813455 USD | 81 | 17 |
| Operating margin | -95.9% | -352.2% | 68 | 13 |
| Net margin | -80.1% | -351.5% | 61 | 13 |
| Return on equity | -99.3% | -89.4% | 50 | 20 |
| 1 year | -18.4% | -35.7% | 64 | 20 |
Peers (25): TENX, BOLD, MREO, BMEA, AURX, ACET, ELOX, CNTB, GOSS, HYPD, ATHE, IBIO, INKT, CELU, ALDX, VRCA, SPRO, PDSB, LONA, GUTS, RNXT, RNTX, INMB, CSBR, FBIO. Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (XLO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow XLO on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to XLO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.